Results 41 to 50 of about 97,638 (260)

Rationing tests for drug-resistant tuberculosis - who are we prepared to miss? [PDF]

, 2016
BACKGROUND: Early identification of patients with drug-resistant tuberculosis (DR-TB) increases the likelihood of treatment success and interrupts transmission.
A Faustini, A Pantoja, A Pooran, A Vassall, C Fitzpatrick, D Martínez, D Menzies, DAJ Moore, DAJ Moore, David A. J. Moore, E Tortoli, EA Kendall, EL Corbett, GJ Churchyard, JC Feres, Jon S. Friedland, Jorge Coronel, K Kliiman, KAK Angeby, L Caviedes, Laura J. Martin, Louis Grandjean, Luz Caviedes, MA Espinal, Martha H. Roper, O Oxlade, P Miotto, PG Suárez, PT Kent, Robert H. Gilman, SS Shin, V Boonsarngsuk, World Health Organization, World Health Organization, World Health Organization, World Health Organization   +35 more
core   +4 more sources

False rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patients

Southern African Journal of HIV Medicine, 2019
Background: A small proportion of false rifampicin resistant results have previously been reported using GeneXpert MTB/RIF version G4 on sputum samples; however, this has not been investigated for urine samples in HIV-associated tuberculosis (TB ...
Charlotte Schutz, Amy Ward, Rosie Burton, Mark P. Nicol, Liz Blumenthal, Graeme Meintjes, Andrew D. Kerkhoff   +6 more
doaj   +1 more source

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.

PLoS ONE, 2020
BackgroundPakistan is among top five high burden countries for tuberculosis and drug resistant TB. Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is 8.3% (95%CI: 7.0-10.7) and resistance to fluoroquinolone is higher
Sabira Tahseen, Faisal Masood Khanzada, Alamdar Hussain Rizvi, Mahmood Qadir, Aisha Ghazal, Aurangzaib Quadir Baloch, Tehmina Mustafa   +6 more
doaj   +1 more source

Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis [PDF]

, 2016
Background Tuberculosis remains a major public health challenge for India. Various studies have documented different levels of TB and multi-drug resistant (MDR) TB among diverse groups of the population.
Arinaminpathy, N, Boehme, C, Denkinger, C, Dewan, P, Kulsange, S, Nair, SA, Paramsivan, CN, Raizada, N, Sachdeva, KS, Schumacher, S   +9 more
core   +1 more source

Diagnosis of rifampicin-resistant tuberculosis: Discordant results by diagnostic methods

African Journal of Laboratory Medicine, 2018
The performance of the Xpert© MTB/RIF and MTBDRplus assays for the detection of rifampicin resistant Mycobacterium tuberculosis was compared to culture-based drug susceptibility testing in 30 specimens with rifampicin-resistant and rifampicin ...
Winnie Mwanza, Deborah Milimo, Maureen M. Chilufya, Nkatya Kasese, Maina C. Lengwe, Stembiso Munkondya, Petra de Haas, Helen Ayles, Monde Muyoyeta   +8 more
doaj   +1 more source

Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens [PDF]

Journal of Medical Microbiology, 1998
Rifampicin is an antibiotic mostly used to treat tuberculosis and leprosy, and, occasionally, other diseases. Resistance is due to alterations in membrane permeability or to mutation in the rpoB gene coding for mRNA polymerase. Both these mechanisms originate via chromosomal mutation.
S, Chandrasekaran, D, Lalithakumari
openaire   +2 more sources

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB [PDF]

The International Journal of Tuberculosis and Lung Disease, 2020
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB). There are multiple ongoing clinical trials aiming to build a robust evidence base to guide RR/MDR-TB treatment, and both observational studies and ...
Cox, V., Mckenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., Ustero, P., Udwadia, Z., Triviño-Duran, L., Tommasi, M., Skrahina, A., Seddon, J., Rodolfo, R., Rich, M., Padanilam, X., Oyewusi, L., Ohler, L., Lungu, P., Loveday, M., Khan, U., Khan, P., Hughes, J., Hewison, C., Guglielmetti, Lorenzo, Furin, J.   +24 more
openaire   +3 more sources

Resistance of Mycobacterium tuberculosis strains to Rifampicin: A systematic review and meta-analysis

Heliyon, 2019
Introduction: Antitubercular drug resistance strain is a horrifying barrier to effective TB treatment and prevention. The present study aimed to determine the prevalence and geographical distribution of rifampicin-resistance M. tuberculosis (MTB) strains.
Seifu Gizaw Feyisa, Ahmed Abdulahi Abdurahman, Worku Jimma, Eshetu Ejeta Chaka, Jalil Kardan-Yamchi, Hossein Kazemian   +5 more
doaj   +1 more source

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021
Background: Rifampicin resistant tuberculosis (RR-TB) was frequently detected in Suriname after the introduction of Xpert MTB/RIF in 2012. Subsequent phenotypic drug-susceptibility testing (DST) was not conclusive at that moment, while RR-TB patients ...
F.A. Gopie, E. Commiesie, S. Baldi, M. Kamst, D. Kaur, W.C.M. de Lange, P.S. Pinas, D. Stijnberg, M. Wongsokarijo, C.W.R. Zijlmans, R. de Zwaan, D. van Soolingen, S.G.S. Vreden, G. de Vries   +13 more
doaj   +1 more source

Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis

Bangabandhu Sheikh Mujib Medical University Journal, 2023
Background:  Multidrug-resistant tuberculosis (MDR-TB) is a global public health problem. Rifampicin (RIF) resistance has been used as a surrogate marker for MDR-TB but isoniazid (INH) resistance within RIF resistance cases is little known. This study aimed to determine the proportion of INH resistance among RIF-resistant MTB.
Naomee Shareef, Ahmed Abu Saleh, Abu Naser Ibne Sattar, Shaheda Anwar   +3 more
openaire   +2 more sources